Pfizer reported third-quarter results today, that topped Wall Street expectations, and the drugmaker raised its full-year 2026 guidance for both revenue and adjusted earnings per share. How did Pfizer’s Q3 compare with estimates? Revenue came in at $16.6 billion, above the $15.87 billion analysts expected. Adjusted earnings per share were 87 cents, well ahead of […]

The postPfizer Q3 2026: What is verified and what is notappeared first onRolling Out.